Cancer Genetics, Inc. is an emerging leader in enabling precision medicine for oncology through the use of molecular markers and information. CGIX’s tests, which target difficult to diagnose hematological, urogenital and HPV-associated cancers, are designed to guide prognosis and treatment with the goal of improving outcomes for patients. CGIX is developing a global footprint with locations in the US, India and China. It has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC, and the National Cancer Institute, and its state-of-the-art reference labs are CLIA-certified and CAP-accredited with licensure from several states including New York State.

CGI’s unique business model positions the company as a global partner of choice for oncology development and diagnostics from bench to bedside. It has built substantial partnerships with biotech and pharmaceutical companies, and is now working with 9 of the top 10 global biopharmas, supporting over 140 clinical trials and studies, including 32 in immune-oncology. CGI's clinical business is delivering critical information to help diagnose and manage cancer care for patients at over 500 cancer centers and hospitals globally. CGI is committed to balancing market execution and continuous innovation which has resulted in revenue growing at a 42% CAGR over the last five years. Additionally, CGI’s first breakthrough in NGS-based liquid biopsy tests and new partnerships and collaborations at the forefront of machine learning, big data and artificial intelligence with Mendel AI and Lantern Pharma are expected to position CGI for strong year over year revenue growth. With a commitment to managing operating expenses and margin improvements, CGIX is on target for near-term profitability. Three wall street analysts have buy ratings on CGIX, with target prices $6.00, $6.00 & $11.00.


  • Record biopharma demand in 2Q17 with $7.1 million in new contract bookings for Biopharma Services
    • CGIX generated $6.6 million revenue in 2Q17
    • Clinical services revenue increased to $3.0 million, up 20% YOY;
    • Strengthened balance sheet with $16 million equity financing arrangement

  • Launched FDA-approved universal companion diagnostic for lung cancer, in partnership with ThermoFisher in 2Q17

  • Completed transformative acquisition of vivoPharm in August 2017
    • vivoPharm adds new customers and opens cross-selling opportunities
    • History of success: Supported 200+ IND submissions for innovative therapies

  • CGIX is powering over 170 active clinical trials and studies with 32 focused in immuno-oncology

  • Launched Next Generation Sequencing (NGS) Liquid Biopsy Test for Lung Cancer Patients

  • Provides comprehensive coverage of 11 critical genes and 150+ hotspots related to lung cancer

  • Strategic Agreements at With Leading Artificial Intelligence Companies to Expand Capabilities and Value to Oncology Community
    • Partnering with Lantern Pharma to using AI and genomic profiling to rescue drugs
    • Partnering with to match cancer patients to clinical trials based on both genomic data and clinical records

More Information | Company Website


Investor Contact Info:

RedChip Companies Inc.
1017 Maitland Center Commons Blvd.
Maitland, FL 32751
(407) 644-4256


"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market